Company / Free Cash Flow
Jazz Pharmaceuticals Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$1.3B
FY2025
5-year range
$736.3M / $1.4B
FY2021-FY2025
Trend
-4.5%
vs FY2024
Sector context
#13 of 194
Health Care
What the data says
Among 194 Health Care companies, Jazz Pharmaceuticals is in the top 7% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from $371M in FY2016 to $1.4B in FY2024.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +10.7%. Top quartile in the Health Care sector.
Improved from $1.1B to $1.3B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +13.6%
- 5-Year CAGR
- +10.7%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 194This company $1.3B Sector average $470.8M
▼
+175.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +10.7%, indicating consistent growth.
- In FY2025, free cash flow decreased 4.5% year-over-year.
- Ranks #13 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | -4.5% |
| FY2024 | $1.4B | +27.1% |
| FY2023 | $1.1B | +20.7% |
| FY2022 | $884.6M | +20.2% |
| FY2021 | $736.3M | -5.4% |
| FY2020 | $778.5M | +17.2% |
| FY2019 | $664.1M | +14.0% |
| FY2018 | $582.7M | -12.3% |
| FY2017 | $664.1M | +78.9% |
| FY2016 | $371.3M | -25.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026